New cytotoxic drugs for breast cancer and their clinical evaluation.
D006585:Altretamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000609:Aminoacridines / Q000627:therapeutic use; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005708:Gallium / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014751:Vindesine; D009353:Zinostatin / Q000627:therapeutic use
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine; D014747:Vinblastine; D004317:Doxorubicin; D009353:Zinostatin; D005708:Gallium; D006585:Altretamine; D014751:Vindesine; C022048:pentamethylmelamine; D007069:Ifosfamide; C002205:zorubicin; C027235:gallium nitrate; D003630:Daunorubicin